Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
NCT06516887Phase 2Terminated
- Sponsor
- UT Health San Antonio
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bemcentinib and pacritinib in lung adenocarcinoma (2 cohorts), sponsored by UT Health San Antonio. Primary endpoints: Progression Free Survival up to 48 months and Overall Response Rate up to 48 months. Started Dec 2024; status: terminated.
02
Drugs
bemcentinibpacritinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06516887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516887.